PHIP inhibitors belong to a class of chemical compounds designed to target the protein PHIP, which stands for Pleckstrin homology domain-interacting protein. PHIP is a multi-domain protein that plays a crucial role in various cellular processes, particularly in the regulation of signal transduction pathways. This protein is known for its interactions with other signaling molecules and its involvement in the modulation of cellular responses to various external stimuli. PHIP contains several functional domains, including a pleckstrin homology (PH) domain, which is responsible for its binding to certain lipids, and proline-rich regions that interact with other signaling proteins. By inhibiting PHIP, these compounds can potentially disrupt the normal functioning of signaling pathways and cellular responses, influencing various biological processes.
PHIP inhibitors may work through different mechanisms, depending on their specific chemical structures. Some inhibitors may bind directly to the PH domain of PHIP, preventing its interaction with lipid molecules or other binding partners. Others may interfere with the proline-rich regions of PHIP, disrupting its associations with downstream signaling molecules. Through these mechanisms, PHIP inhibitors have the potential to modulate signal transduction pathways and impact cellular processes such as cell growth, proliferation, and differentiation. Ongoing research aims to uncover the precise mechanisms and downstream effects of PHIP inhibition, shedding light on the importance of this protein in cellular biology.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor that can indirectly affect PHIP function by modulating the MAPK/ERK pathway, which is involved in cellular proliferation and survival. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
A BRAF inhibitor that impacts the MAPK/ERK pathway, potentially influencing PHIP-related signaling in cells with BRAF mutations. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
An mTOR inhibitor that can affect PHIP function by modulating cellular growth, proliferation, and survival pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Another mTOR inhibitor, similar to Everolimus, impacting pathways relevant to PHIP's role in cell growth and survival. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A multi-kinase inhibitor that affects various pathways including RAF kinases, potentially influencing PHIP activity indirectly. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A receptor tyrosine kinase inhibitor, impacting pathways in angiogenesis and cell proliferation that may indirectly affect PHIP. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor, potentially influencing cell cycle progression and thus indirectly affecting PHIP function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can affect multiple cellular pathways, potentially influencing PHIP function indirectly. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor, could influence signaling pathways related to PHIP activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
A multi-kinase inhibitor targeting vascular endothelial growth factor receptors, potentially impacting PHIP indirectly. |